


Medium-dose ICS


● Phase 2b: placebo/dupilumab ● Phase 2b: dupilumab/dupilumab
 ● QUEST: placebo/dupilumab ● QUEST: dupilumab/dupilumab

(A) Exposed population




Number of patients			
Phase 2b PBO/DPL	54	54	51
Phase 2b DPL/DPL	186	186	175
QUEST PBO/DPL	235	229	220
QUEST DPL/DPL	494	476	472

(B) ≥ 150 eosinophils/ μ L at PSBL




Number of patients			
Phase 2b PBO/DPL	40	40	38
Phase 2b DPL/DPL	138	138	131
QUEST PBO/DPL	164	160	154
QUEST DPL/DPL	346	334	326

(C) ≥ 300 eosinophils/ μ L at PSBL



Number of patients			
Phase 2b PBO/DPL	20	20	19
Phase 2b DPL/DPL	72	72	68
QUEST PBO/DPL	105	103	100
QUEST DPL/DPL	215	209	201

(D) FeNO ≥ 25 ppb at PSBL



Number of patients			
Phase 2b PBO/DPL	27	27	27
Phase 2b DPL/DPL	92	92	90
QUEST PBO/DPL	134	132	127
QUEST DPL/DPL	249	242	234